236 related articles for article (PubMed ID: 20421572)
1. The multiple sclerosis functional composite: a clinically meaningful measure of disability.
Polman CH; Rudick RA
Neurology; 2010 Apr; 74 Suppl 3():S8-15. PubMed ID: 20421572
[TBL] [Abstract][Full Text] [Related]
2. Binocular low-contrast letter acuity and the symbol digit modalities test improve the ability of the Multiple Sclerosis Functional Composite to predict disease in pediatric multiple sclerosis.
Waldman AT; Chahin S; Lavery AM; Liu G; Banwell BL; Liu GT; Balcer LJ
Mult Scler Relat Disord; 2016 Nov; 10():73-78. PubMed ID: 27919503
[TBL] [Abstract][Full Text] [Related]
3. Psychometrics and normative data for the Multiple Sclerosis Functional Composite: replacing the PASAT with the Symbol Digit Modalities Test.
Drake AS; Weinstock-Guttman B; Morrow SA; Hojnacki D; Munschauer FE; Benedict RH
Mult Scler; 2010 Feb; 16(2):228-37. PubMed ID: 20028710
[TBL] [Abstract][Full Text] [Related]
4. [Long-term application of the multiple sclerosis functional composite test in Debrecen, Hungary].
Mezei Z; Bereczki D; Csiba L; Csépány T
Ideggyogy Sz; 2006 Nov; 59(11-12):442-7. PubMed ID: 17203882
[TBL] [Abstract][Full Text] [Related]
5. The reliability of the MSFC and its components.
Rosti-Otajärvi E; Hämäläinen P; Koivisto K; Hokkanen L
Acta Neurol Scand; 2008 Jun; 117(6):421-7. PubMed ID: 18081910
[TBL] [Abstract][Full Text] [Related]
6. Use of the multiple sclerosis functional composite as an outcome measure in a phase 3 clinical trial.
Cohen JA; Cutter GR; Fischer JS; Goodman AD; Heidenreich FR; Jak AJ; Kniker JE; Kooijmans MF; Lull JM; Sandrock AW; Simon JH; Simonian NA; Whitaker JN
Arch Neurol; 2001 Jun; 58(6):961-7. PubMed ID: 11405811
[TBL] [Abstract][Full Text] [Related]
7. [Application of the Multiple Sclerosis Functional Composite in Debrecen].
Mezei Z; Bereczki D; Csiba L; Csépány T
Ideggyogy Sz; 2005 Mar; 58(3-4):113-8. PubMed ID: 15887414
[TBL] [Abstract][Full Text] [Related]
8. Brain and cord myelin water imaging: a progressive multiple sclerosis biomarker.
Kolind S; Seddigh A; Combes A; Russell-Schulz B; Tam R; Yogendrakumar V; Deoni S; Sibtain NA; Traboulsee A; Williams SC; Barker GJ; Brex PA
Neuroimage Clin; 2015; 9():574-80. PubMed ID: 26594633
[TBL] [Abstract][Full Text] [Related]
9. Paced visual serial addition test in multiple sclerosis.
Nagels G; Geentjens L; Kos D; Vleugels L; D'hooghe MB; Van Asch P; Vuylsteke K; De Deyn PP
Clin Neurol Neurosurg; 2005 Apr; 107(3):218-22. PubMed ID: 15823678
[TBL] [Abstract][Full Text] [Related]
10. Use of the Multiple Sclerosis Functional Composite to predict disability in relapsing MS.
Rudick RA; Cutter G; Baier M; Fisher E; Dougherty D; Weinstock-Guttman B; Mass MK; Miller D; Simonian NA
Neurology; 2001 May; 56(10):1324-30. PubMed ID: 11376182
[TBL] [Abstract][Full Text] [Related]
11. The multiple sclerosis functional composite: a new clinical outcome measure for multiple sderosis trials.
Rudick RA; Cutter G; Reingold S
Mult Scler; 2002 Oct; 8(5):359-65. PubMed ID: 12356200
[TBL] [Abstract][Full Text] [Related]
12. Low-contrast letter acuity testing captures visual dysfunction in patients with multiple sclerosis.
Baier ML; Cutter GR; Rudick RA; Miller D; Cohen JA; Weinstock-Guttman B; Mass M; Balcer LJ
Neurology; 2005 Mar; 64(6):992-5. PubMed ID: 15781814
[TBL] [Abstract][Full Text] [Related]
13. MS functional composite: relation to disease phenotype and disability strata.
Kalkers NF; de Groot V; Lazeron RH; Killestein J; Adèr HJ; Barkhof F; Lankhorst GJ; Polman CH
Neurology; 2000 Mar; 54(6):1233-9. PubMed ID: 10746590
[TBL] [Abstract][Full Text] [Related]
14. Improvement in the multiple sclerosis functional composite score by multi-function swing suspension training program.
Sepehri Far S; Amiri B; Sahebozamani M; Ebrahimi HA
Mult Scler Relat Disord; 2022 Nov; 67():104174. PubMed ID: 36174257
[TBL] [Abstract][Full Text] [Related]
15. Correlations between multiple sclerosis functional composite, expanded disability status scale and health-related quality of life during and after treatment of relapses in patients with multiple sclerosis.
Ozakbas S; Cagiran I; Ormeci B; Idiman E
J Neurol Sci; 2004 Mar; 218(1-2):3-7. PubMed ID: 14759626
[TBL] [Abstract][Full Text] [Related]
16. Multiple Sclerosis Impact Scale (MSIS-29): relation to established measures of impairment and disability.
Hoogervorst EL; Zwemmer JN; Jelles B; Polman CH; Uitdehaag BM
Mult Scler; 2004 Oct; 10(5):569-74. PubMed ID: 15471375
[TBL] [Abstract][Full Text] [Related]
17. Cognitive performance in relapsing remitting multiple sclerosis: a longitudinal study in daily practice using a brief computerized cognitive battery.
Edgar C; Jongen PJ; Sanders E; Sindic C; Goffette S; Dupuis M; Jacquerye P; Guillaume D; Reznik R; Wesnes K
BMC Neurol; 2011 Jun; 11():68. PubMed ID: 21649910
[TBL] [Abstract][Full Text] [Related]
18. The longitudinal relationship between the patient-reported Multiple Sclerosis Impact Scale and the clinician-assessed Multiple Sclerosis Functional Composite.
Costelloe L; O'Rourke K; McGuigan C; Walsh C; Tubridy N; Hutchinson M
Mult Scler; 2008 Mar; 14(2):255-8. PubMed ID: 17942522
[TBL] [Abstract][Full Text] [Related]
19. Should SDMT substitute for PASAT in MSFC? A 5-year longitudinal study.
Brochet B; Deloire MS; Bonnet M; Salort-Campana E; Ouallet JC; Petry KG; Dousset V
Mult Scler; 2008 Nov; 14(9):1242-9. PubMed ID: 18653737
[TBL] [Abstract][Full Text] [Related]
20. Clinical outcome measures for research in multiple sclerosis.
Balcer LJ
J Neuroophthalmol; 2001 Dec; 21(4):296-301. PubMed ID: 11756863
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
